CompletedPhase 1NCT02315612
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
Studying ALK-positive anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Nirali N Shah, M.D.National Cancer Institute (NCI)
- Intervention
- CD22-CAR(biological)
- Enrollment
- 134 enrolled
- Eligibility
- 3-39 years · All sexes
- Timeline
- 2014 – 2024
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02315612 on ClinicalTrials.gov